Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,604,559
  • Shares Outstanding, K 62,516
  • Annual Sales, $ 434,430 K
  • Annual Income, $ 275,190 K
  • EBIT $ 19 M
  • EBITDA $ 13 M
  • 60-Month Beta 2.19
  • Price/Sales 12.57
  • Price/Cash Flow 19.33
  • Price/Book 8.46

Options Overview Details

View History
  • Implied Volatility 38.62% (-2.89%)
  • Historical Volatility 32.66%
  • IV Percentile 2%
  • IV Rank 2.93%
  • IV High 138.06% on 02/21/25
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 13) 5.10 (5.69%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 175
  • Volume Avg (30-Day) 358
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 14,165
  • Open Int (30-Day) 17,572
  • Expected Range 84.55 to 94.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 5
  • High Estimate -0.16
  • Low Estimate -0.73
  • Prior Year 1.98
  • Growth Rate Est. (year over year) -126.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.70 +16.88%
on 11/07/25
90.85 -1.32%
on 11/26/25
+11.77 (+15.11%)
since 11/05/25
3-Month
54.50 +64.50%
on 09/09/25
93.25 -3.86%
on 10/10/25
+29.12 (+48.11%)
since 09/05/25
52-Week
33.70 +166.02%
on 02/25/25
93.25 -3.86%
on 10/10/25
+47.97 (+115.09%)
since 12/05/24

Most Recent Stories

More News
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications...

PTGX : 89.65 (+2.66%)
PTIX : 1.6700 (-0.60%)
Protagonist Therapeutics: Q3 Earnings Snapshot

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 89.65 (+2.66%)
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted...

PTGX : 89.65 (+2.66%)
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the...

PTGX : 89.65 (+2.66%)
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic...

PTGX : 89.65 (+2.66%)
Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

PTGX : 89.65 (+2.66%)
JNJ : 201.93 (-0.27%)
KVUE : 16.93 (-0.35%)
Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Protagonist Therapeutics, with a price target of $112.00. The company’s shares closed last Friday at $87.00.Elevate...

PTGX : 89.65 (+2.66%)
Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics. The company’s shares closed last Friday at $87.00.Elevate Your Investing Strategy:...

PTGX : 89.65 (+2.66%)
Truist Financial Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $76.00. The company’s shares closed yesterday at $65.47.Elevate Your...

PTGX : 89.65 (+2.66%)
H.C. Wainwright Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $80.00. The company’s shares closed yesterday at $65.47.Elevate Your Investing...

PTGX : 89.65 (+2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 93.35
2nd Resistance Point 91.76
1st Resistance Point 90.71
Last Price 89.65
1st Support Level 88.07
2nd Support Level 86.48
3rd Support Level 85.43

See More

52-Week High 93.25
Last Price 89.65
Fibonacci 61.8% 70.50
Fibonacci 50% 63.47
Fibonacci 38.2% 56.45
52-Week Low 33.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar